Sanofi Sees High Single-Digit Sales Growth in 2026, Announces 1 Billion Euro Buyback
Sanofi reported guidance for 2026 sales to rise by a high-single-digit percentage, underpinned by continued strength in its Dupixent asthma franchise and several newly added medicines. The company also indicated business operating income will increase marginally faster than sales this year and unveiled a 1 billion euro share repurchase plan, follow…